Live at IDWeek 2014

Switching to single-tablet co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir (EVG/COB/FTC/TDF) from a multi-tablet ritonavir-boosted protease inhibitor (PI + RTV) with emtricitabine and tenofovir DF (FTC/TDF) regimen significantly increased rates of virologic suppression and declined fasting triglycerides in patients with HIV-1 infection.

Substantial proportions of children who received the MenACWY-CRM conjugate vaccine between the ages of 2 and 10 years continued to have persistent antibodies against all four serogroups, with robust increases in antibody titers after a booster dose 5 years following the primary vaccination series

Concomitant administration of a licensed quadrivalent human papillomavirus (HPV4) vaccine and bivalent rLP2086, an investigational Neisseria meningitidis serogroup B (MnB) vaccine, generated robust immune responses to both vaccines in healthy adolescents.

The safety and immunogenicity of the investigational combination vaccine, DTaP5-IPV-Hib-HepB, when given as a 3-dose infant series, were comparable to equivalent licensed component vaccines.

Efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) in the prevention of vaccine-type community-acquired pneumonia (VT-CAP) or invasive pneumococcal disease (VT-IPD) declined with age.

Ceftaroline fosamil was effective in treating acute bacterial skin and skin structure infections (ABSSSIs) in obese patients and in patients with diabetes.

Two investigational formulations of meningococcal MenABCWY vaccines have shown comparable immunogenicity to the licensed vaccines (MenACWY-CRM) and serogroup B (4CMenB), and the full outer membrane vesicle formulation gave higher GMT responses against B test strains.

Revaccination of children with live-attenuated influenza vaccine (LAIV) over 2 consecutive seasons did not reduce vaccine efficacy, and was similar to, or higher than, efficacy of a single LAIV administration in the second season.

The investigational Intradermal (ID) Quadrivalent Inactivated Influenza Vaccine (IIV4-ID) tested in a Phase 3 clinical trial during the 2012-13 influenza season produced antibody responses to B strains that were superior to a licensed split-virion trivalent influenza vaccine (IIV3-ID) containing the alternate strain, and noninferior for the A and matched B strains.

Initial treatment of patients hospitalized with aspiration pneumonia with anaerobe-specific antibiotics did not influence mortality or length of stay, compared to those without initial anaerobe-specific antibiotics, but patients without initial anaerobe coverage were more likely to change antibiotics